New Faculty Recruitment

WINTER 2017 New Faculty Recruitment Latha Palaniappan, MD, MS was recently recruited by the Cardio- vascular Institute, Stanford Primary Care and Population Health, and Cardiovascular Medicine as a new faculty member. Her innova- tive research focuses on health disparities, epidemiology, and prevention. She will be focusing her clinical efforts on Precision Health in Primary Care, working with colleagues at Stanford to start evi- dence based genetic and pharmacogenetic testing in primary care. CVI Welcomes Prior to this role, she was the Medical Director of Clinical Research at Palo Alto Medical Foundation (PAMF) and co-founder of the Prevention and Awareness for South Asians New Associate program (PRANA). Director, Natalie Lui, MD, MAS is joining the Division of Thoracic Surgery as Hana Lee, MPH an Assistant Professor. She studied physics as an undergraduate at Harvard and attended medical school at Johns Hopkins Universi- CVI is excited to welcome Hana Lee, ty. She completed residency in General Surgery at the University of MPH, as the new Associate Director. California, San Francisco, including research in the UCSF Thoracic Previously, she was the Director of Oncology Laboratory and a Masters in Advanced Studies in clinical Strategic Initiatives at the Stanford research. She did her fellowship in Thoracic Surgery at Massachu- Center for Population Health Sciences setts General Hospital, including visiting rotations at Memorial Sloan Kettering and the and an epidemiologist at the Universi- Mayo Clinic. Her clinical focus extends to all aspects of general thoracic surgical diseas- ty of California, San Francisco. She re- es, and her research focus is in thoracic oncology. ceived M.P.H in Epidemiology/Health Policy and Management at the Johns Division of Pediatric Cardiology in the Department of Pediatrics is Hopkins Bloomberg School of Public pleased to announce Lillian Su, MD as Clinical Assistant Professor. Dr. Health and B.A. in Psychology at the Su is a pediatric cardiac intensivist, and her clinical responsibilities University of San Francisco. Her broad will be focused in the Cardiovascular Intensive Care Unit (CVICU) at expertise, creativity, and enthusiasm Lucile Packard Children’s Hospital. Her research interests focus on the for strategic discoveries will be an as- utilization of simulation training and education to improve patient set to the growth and diversity of the care and team functionality in the critical care environment. Dr. Su Stanford Cardiovascular Institute. will also lead the Children’s Heart Center Simulation Program as its Medical Director. PCBC Workshop: Stem and Progenitor Cells UPCOMING CVI SYMPOSIA in Cardiovascular Precision Save the date: Medicine APRIL 25, 2017 DUKE Stanford - China 2nd Annual STANFORD Cardiovascular Stanford Drug Discovery Conference Research Symposium APRIL 24, 2017 SEPTEMBER 21–22, 2017 cvi.stanford.edu | 1 2017 Stanford Drug Discovery Conference April 24, 2017 | 8:30 am – 6 pm | Li Ka Shing Center for Learning & Knowledge (LKSC) Advances in basic research and technology now affords us the unique opportunity to test novel diagnostic methods and therapeutics. The conference takes advantage of the collective experience and expertise from industry, academia, policy and venture capital towards drug discovery and personalized medicine. WELCOME Joseph Wu, MD, PhD David Entwistle, MHSA Christopher G. Dawes, MBA Director , Stanford Cardio- President and Chief Executive President and Chief Execu- vascular Institute; Simon H. Officer, Stanford Health Care tive Officer, Lucile Packard Stertzer Professor of Medicine Children’s Hospital (Cardiology) & Radiology KEYNOTE SPEAKERS Thomas Südhof, MD, PhD Robert Califf, MD 2013 Nobel Laureate; Avram Goldstein Professor, Donald F. Fortin Professor of Cardiology, Duke School Stanford School of Medicine and Professor, by courtesy, of Medicine; Former Commissioner of U.S. Food and Drug of Neurology and of Psychiatry and Behavioral Sciences Administration BENCH TO BEDSIDE: INDUSTRY - PROMISES BENCH TO BEDSIDE: CARDIOVASCULAR MEDICINE & CHALLENGES CANCER THERAPIES Daria Mochly-Rosen, PhD James (Jay) E. Bradner, MD Alan Ashworth, PhD George D. Smith Professor President, Novartis Institutes Director, UCSF Helen Diller in Translational Medicine; for BioMedical Research Family Comprehensive Founder and President, Cancer Center; Senior Vice SPARK Global President, Cancer Services Sean E. Harper, MD of UCSF Health Shaun R. Coughlin, MD, PhD Executive Vice President, Director, Cardiovascular Research and Development, Gideon Bollag, PhD Research Institute, UCSF Amgen Chief Executive Officer of Pelxxikon David Altshuler, MD, PhD Eric Olson, PhD Executive Vice President, Professor, Chairman of Global Research and Chief Shivaani Kummar, MD Molecular Biology; Scientific Officer, Vertex Phar- Professor of Medicine (Oncol- UT Southwestern Medical maceuticals ogy) and of Radiology (Mo- Center, Dallas lecular Imaging Program), Andrew Plump, MD, PhD Stanford Stephen Quake, PhD Chief Medical Lee Otterson Professor in the and Scientific Officer, SESSION CHAIR School of Engineering and Takeda Pharmaceuticals Beverly S. Mitchell, MD Professor of Bioengineering of Director, Stanford Cancer Insti- Applied Physics and, by courte- SESSION CHAIR tute; George E. Becker Profes- sy, of Physics; Co-President of Robert A. Harrington, MD sor in Medicine and Professor, the Chan Zuckerberg Biohub Arthur L. Bloomfield Professor by courtesy, of Chemical and of Medicine; Chair, Stanford Systems Biology SESSION CHAIR Department of Medicine Helen M. Blau, PhD Donald and Delia Baxter Foundation Professor, Stan- REGISTER ford; Director, Baxter Labora- & SUBMIT POSTERS tory for Stem Cell Biology cvi.stanford.edu Organizing Committee: Joseph C. Wu, MD, PhD; Sanjay V. Malhotra, PhD; Mark Mercola, PhD cvi.stanford.edu | 2 Stanford study creates a score card index for heart-damaging chemotherapy drugs By Krista Conger Researchers at the Stanford University School of Medicine used say can be used to predict with confidence the likely clinical outcomes heart-muscle cells made from stem cells to rank commonly used che- of drugs still under development. motherapy drugs based on their likelihood of causing lasting heart , , and their colleagues created heart damage in patients. Arun Sharma Wesley McKeithan muscle cells called cardiomyocytes from induced pluripotent stem Drugs known as tyrosine kinase inhibitors cells, or iPS cells, from 11 healthy people and two people with kidney can be an effective treatment for many cancer. They grew the lab-made cardiomyocytes in a dish and tested types of cancers, but they also have severe the effects of 21 commonly used tyrosine kinase inhibitors on the cells. and sometimes fatal side effects. Using lab- They found that treatment with drug levels equivalent to those tak- grown heart cells, Stanford researchers were en by patients often caused the cells to beat irregularly and begin to able to assess the drugs’ various effects on die. The cells also displayed differences in the electrophysiological heart-muscle cells, including their survival Arun Sharma, PhD signaling that controls their contraction. The researchers used these and ability to beat rhythmically and effec- and other measurements to develop a “cardiac safety index” for each tively, to respond appropriately to electro- drug. physiological signals, and to communicate with one another. The current study mirrors another program by Wu’s lab that was published in April of 2016 in Nature Medicine. That research focused on The researchers found that their assay can the toxic effect of a chemotherapy drug called doxorubicin on iPS accurately identify those tyrosine kinase in- cell-derived cardiomyocytes. Doxorubicin, which indiscriminately hibitors already known to be the most dan- kills any replicating cells, is increasingly being replaced by more tar- Wesley McKeithan gerous in patients. In the future, they believe geted, cancer-specific therapies such as the tyrosine kinase inhibitors their system may prove useful in the early tested in the current study. stages of drug development to preemptively screen new compounds for cardiotoxicity. Stanford co-authors are former instructor of the Cardiovascular Insti- tute Paul Burridge, PhD; graduate student Wesley McKeithan; post- “This type of study represents a critical step forward from the usual doctoral scholars Praveen Shukla, PhD, Haodi Wu, PhD, and Alexandra process running from initial drug discovery and clinical trials in hu- Holmström, PhD; Visiting Scholar Tomoya Kitani, MD; Cardiovascular man patients,” said Joseph C. Wu, MD, PhD, Director of the Stanford Institute instructors Nazish Sayed, MD, PhD, Elena Matsa, PhD, and Cardiovascular Institute and a professor of cardiovascular medicine Jared Churko, PhD; medical student Anusha Kumar, undergraduate and radiology. “It will help pharmaceutical companies better focus student Yuan Zhang; assistant professor of medicine Alice Fan, MD; their efforts on developing safer drugs, and it will provide patients associate professor of medicine Sean Wu, MD, PhD; and professor of more effective drugs with fewer side effects.” medicine Mark Mercola, PhD, in a study published in Science Trans- Validating the researchers’ newly designed cardiac safety index on lational Medicine. drugs with extensive clinical track records is necessary before the as- Read more: https://http://stm.sciencemag.org/content/9/377/eaaf2584 About the Stanford Cardiovascular Institute The Institute currently consists of over

Load more